BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature...
BioCentury | May 13, 2013
Clinical News

Royal DSM preclinical data

...In mice, single doses of 1.7, 5 and 15 µg recombinant hemagglutinin (rHA) vaccine with or...
...days following the second vaccination. Data were published in PloS ONE. The vaccine comprises an rHA...
...culture-based methods (see BioCentury, Oct. 15, 2012). Royal DSM N.V. (Euronext:DSM), Heerlen, the Netherlands Product: RHA...
BioCentury | Dec 13, 2010
Clinical News

H5N1 influenza vaccine: Phase I started

...Product: H5N1 influenza vaccine ( HAI-05 ) Business: Infectious Molecular target: NA Description: Recombinant hemagglutinin (rHA...
BioCentury | Jul 16, 2009
Distillery Therapeutics

Indication: Cancer

...Cancer Sarcoma Ewing's sarcoma breakpoint region 1 (EWSR1; EWS-Fli1); DEAH (Asp-Glu-Ala-His) box polypeptide 9 (DHX9; RHA...
...RHA) In vitro and mouse studies identified small molecule inhibitors of interactions between EWS-FLI1 and RHA...
...treat Ewing's sarcoma. Ewing's sarcoma tumors express the oncogenic fusion protein EWS-Fli1, which binds to RHA...
BioCentury | Aug 30, 2004
Tools & Techniques

Sugar-coated delivery

...next joined the non-mammalian sugar alpha-L-rhamnopyranose (Rha) to doxorubicin to make a prodrug named Rha-DOX. Rha-capped...
...that Rha-DOX has not been optimized. For now, Glycoform has tested only intravenous administration of Rha-DOX...
...said. "Rha-DOX is available for partnering," said CEO Ian Rubin. The company may not move Rha-DOX...
BioCentury | May 3, 2004
Product Development

Protein Sciences: No Yolk

...company's BEVS technology produces recombinant hemagglutinin (rHA) in serum-free insect cells. FluBlOk consists of three rHA...
BioCentury | May 14, 2001
Company News

Symyx, Rhodia deal

...SMMX will use its combinatorial technologies to discover improved materials for RHA’s specialty chemical business. RHA...
...have exclusive commercialization rights to materials from the collaboration. SMMX also will receive payments on RHA’s...
...of products that incorporate the discovered materials. Symyx Technologies Inc. (SMMX), Santa Clara, Calif. Rhodia (RHA...
BioCentury | May 9, 2001
Company News

Symyx chemicals deal with Rhodia

...SMMX will use its combinatorial technologies to discover improved materials for RHA's specialty chemical business. RHA...
...have exclusive commercialization rights to materials from the collaboration. SMMX also will receive payments on RHA's...
BioCentury | Jul 31, 2000
Company News

ChiRex, Rhodia deal

...product development and manufacturing services to the pharmaceutical industry. ChiRex Inc. (CHRX), Stamford, Conn. Rhodia (RHA...
Items per page:
1 - 10 of 22